Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

h and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... DIEGO , March 5, 2015  In response ... in Miami, FL on February ... are both of strong financial health and their SUDOSCAN® ... clinical research has indicated. Furthermore, Impeto prefers to have the ... There are more than 40 articles written by ...
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report 2015 ... current state of the biologics and biosimilars industry. ... of the industry including definitions, classifications, applications and ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... Researchers at North Carolina State University have created a ... which retains these properties under extremely high temperatures ... applications, such as engine components that are exposed to ... is made up of nanoscale crystals is far stronger ...
... PACS milestone is a testament to tight integration and ... ... Inc. (Nasdaq: AMCS ), a,leader in radiology and medical image ... Vision Series(TM),PACS at more than 100 facilities that use MEDITECH(TM) as ...
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... the,Ministry of Health has purchased approximately RMB 20 ... vaccine, Healive(R), to,vaccinate people living in the disaster ... shipments of the Healive vaccine to,Sichuan, Shanxi and ...
Cached Biology Technology:AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 3Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims 2
(Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... sinister about epilepsy: the disease affects the very core ... lead to seizures throughout the body or in parts of ... possible. The causes are still only partially understood but ... or metabolic diseases have been implicated. Epilepsy is not ...
... February 1, 2013 Poor impulse control contributes ... rewarding substances, like food, alcohol, and other drugs. ... FDA-approved medications for alcoholism, like naltrexone (Revia) and ... by curbing cravings and creating unpleasant reactions to ...
... levels of greenhouse gases, particularly carbon dioxide (CO2), ... fuels, deforestation, cultivation of grasslands, drainage of the ... shifts in climate patterns have led scientists to ... and to develop methods to evaluate how changes ...
Cached Biology News:Cats and humans suffer from similar forms of epilepsy 2If you are impulsive, take modafinil and count to 10 2New protocol recommendations for measuring soil organic carbon sequestration 2New protocol recommendations for measuring soil organic carbon sequestration 3New protocol recommendations for measuring soil organic carbon sequestration 4
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
... Kit - Monolayer is a system designed for ... monolayer in a serum-free environment. The kit contains ... has been optimized for neural stem cell expansion ... & Development 10 :3129). Human fibroblast growth ...
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
... E. coli strain containing an overproducing ... M-MLV Reverse Transcriptase catalyzes the polymerization of ... hybrids(1). Full-length copies of large mRNAs, >10 ... has a much lower RNase H activity ...
Biology Products: